Helix BioPharma Responds to Market Activity

Core Viewpoint - Helix BioPharma Corp. is not aware of any undisclosed material information that could explain the recent increase in its share price and trading volume [1] Company Overview - Helix BioPharma is a clinical-stage oncology company focused on developing solutions for hard-to-treat cancers [2] - The company's leading product is Tumor Defense Breaker™ L-DOS47, an antibody-enzyme conjugate aimed at enhancing the effectiveness of therapies for CEACAM6-expressing tumors [2] - L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its foundation with the company's next-generation bi-specific antibody-drug conjugates currently in discovery [2] - Helix is also advancing two pre-IND candidates: LEUMUNA™, an oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA™, a first-in-class oral gemcitabine prodrug designed for advanced cancers [2] Stock Information - Helix BioPharma is listed on multiple exchanges: TSX (HBP), OTC PINK (HBPCD), and FWB (HBP0) [3]